Leo Lens Pharma appoints Dan Myers as CEO

ByKate Burba

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Dan Myers has been appointed as CEO of Leo Lens Pharma, according to a press release.

With more than 35 years of ophthalmic pharmaceutical experience and 21 years in leadership roles, Myers was the co-founder and CEO of Alimera Sciences and a founding employee of Novartis Ophthalmics.

Leo Lens is currently in the process of submitting an investigational new drug application to the FDA for a proprietary contact lens to treat glaucoma. The company’s MediPrint printing technology process is used to manufacture the lens, which allows for the continuous delivery of bimatoprost for 7 days.

“I’m excited and honored to be joining Leo Lens at such a pivotal time in its progression,” Myers said in the release. “Our enterprise is poised to address the significant unmet need in glaucoma treatment by successfully advancing the development of our proprietary MediPrint process. We are currently building a proven pharmaceutical and ophthalmic management team to execute on this strategy and to create what I believe will be a very successful company.”